Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31191247 | 0.95 | OPRD1 (0.48) | OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL31191293 | 0.95 | OPRD1 (0.49) | OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL29569246 | 0.90 | NTSR1 (0.44) | OPRD1NTSR1NTSR2SORT1APLNR | |
| SCHEMBL30933084 | 0.88 | NTSR1 (0.49) | OPRD1NTSR1NTSR2SORT1APLNR | |
| SCHEMBL29800900 | 0.87 | NTSR1 (0.48) | OPRD1NTSR1NTSR2SORT1 | |
| SCHEMBL29399877 | 0.86 | NTSR1 (0.46) | OPRD1NTSR1NTSR2SORT1APLNR | |
| SCHEMBL21312656 | 0.86 | APLNR (0.45) | OPRD1NTSR1APLNR | |
| SCHEMBL31067246 | 0.86 | PTPN1 (0.43) | OPRD1NTSR1NTSR2APLNR | |
| SCHEMBL29800934 | 0.85 | PTPN1 (0.42) | OPRD1NTSR1APLNR | |
| SCHEMBL29421978 | 0.85 | APLNR (0.51) | OPRD1NTSR1NTSR2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166266-B | Anti-mesothelin constructs and uses thereof | 上海偌妥生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-12215130-B2 | Cytokine-albumin binding moiety fusion proteins and uses thereof | ANWITA BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12091438-B2 | Anti-mesothelin constructs and uses thereof | ANWITA BIOSCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091438-B2 | Anti-mesothelin constructs and uses thereof | IL15, IL15RA, EPS15 | OPRD1 4260/4885NTSR1 518/4885NTSR2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.